Skip to main navigation
Skip to search
Skip to main content
Hanze University of Applied Sciences Home
English
Nederlands
Search content at Hanze University of Applied Sciences
Home
Profiles
Research units
Projects
Research output
Datasets
Activities
Press/Media
Prizes
Topical treatment for facial burns
Cornelis J Hoogewerf
, M Jenda Hop
,
Marianne K Nieuwenhuis
, Irma Mmh Oen
, Esther Middelkoop
, Margriet E Van Baar
Dutch Burns Foundation
Martini Hospital - Burncentre Groningen
Amsterdam UMC Location Vrije Universiteit, Department of Plastic, Reconstructive and Hand Surgery
Burncentre Beverwijk - Department of Plastic and Reconstructive Surgery
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Topical treatment for facial burns'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Confidence Interval
100%
Topical Treatment
100%
Facial Burns
100%
Antimicrobial
66%
Topical Antimicrobials
66%
Moist Exposed Burn Ointment
50%
Wound Healing
41%
Silver Sulfadiazine
41%
Randomized Controlled Trial
33%
Nonbacterial
33%
Skin Substitute
33%
Scar Quality
33%
Wound Infection
33%
Risk Ratio
33%
Topical Intervention
25%
Patient Satisfaction
16%
Length of Hospital Stay
16%
Adverse Effects
16%
Burn Injury
16%
Reduced Time
16%
Quality Satisfaction
16%
Tissue-engineered Skin Substitutes
16%
Ovid
16%
Cerium
16%
Aquacel Ag
16%
Helix Aspersa
16%
Complete Healing
16%
Porcine
16%
Health Technology
8%
MEDLINE
8%
CINAHL
8%
High Risk
8%
Intervention Effect
8%
Evidence-based
8%
Embase
8%
EBSCO
8%
Meta-analysis
8%
Health Problems
8%
Cochrane
8%
Risk of Bias
8%
Data Extraction
8%
Treatment Effect
8%
Hazard Ratio
8%
Clinical Trial Registry
8%
Means of Communication
8%
Infection Risk
8%
Antibacterial Agents
8%
Burn Care
8%
Burn Center
8%
Person Identity
8%
Topical Agents
8%
In-process
8%
Expressive Means
8%
Randomized Methods
8%
Risk of Bias Assessment
8%
Certainty Effect
8%
Grade Estimation
8%
Background Pain
8%
Biological Dressings
8%
Wound Area
8%
Allograft
8%
Mafenide Acetate
8%
Sequence Generation
8%
Sulphadiazine
8%
Head-and-neck Region
8%
Bacitracin
8%
Deep Partial Thickness Burns
8%
Growth Hormone Treatment
8%
Certainty of Evidence
8%
Xenograft
8%
Enzymatic Debridement
8%
Gentamicin
8%
Surgery Pain
8%
Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
8%
Review Authors
8%
Cochrane Central Register of Controlled Trials
8%
Superficial Burns
8%
Allocation Concealment
8%
Procedural Pain
8%
Event Rate
8%
Nursing and Health Professions
Thermal Burn
100%
Topical Treatment
100%
Antiinfective Agent
100%
Confidence Interval
70%
Artificial Skin
41%
Wound Healing
41%
Ointment
35%
Wound
35%
Sulfadiazine
35%
Cream
23%
Wound Infection
23%
Patient Satisfaction
11%
Steri-Strip
11%
Antimicrobial Agent
11%
CINAHL
5%
Hormonal Therapy
5%
Meta Analysis
5%
Cochrane Library
5%
Embase
5%
Randomization
5%
Growth Hormone
5%
Biological Dressing
5%
Hydrogel
5%
Hazard Ratio
5%
Data Extraction
5%
Topical Agent
5%
Xenograft
5%
Bacitracin
5%
Mafenide Acetate
5%
Gentamicin
5%
Debridement
5%
Allograft
5%
Surface Area
5%
Procedural Pain
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Diseases
5%
Medicine and Dentistry
Thermal Burn
100%
Antiinfective Agent
100%
Topical Treatment
100%
Wound Healing
41%
Wound
35%
Sulfadiazine
35%
Randomized Controlled Trial
23%
Wound Infection
23%
Patient Satisfaction
11%
Helix
11%
Steri-Strip
11%
Antimicrobial Agent
11%
Adverse Effect
11%
Neck
5%
Meta-Analysis
5%
Clinical Trial
5%
Hazard Ratio
5%
Allograft
5%
Health Technology
5%
Debridement
5%
Xenograft
5%
Bacitracin
5%
Mafenide Acetate
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Growth Hormone
5%
Gentamicin
5%
Procedural Pain
5%
Topical Agent
5%
Endocrine Therapy
5%
Diseases
5%
Primary Outcome
5%
Pharmacology, Toxicology and Pharmaceutical Science
Burn
100%
Antiinfective Agent
100%
Wound Healing
41%
Wound
35%
Sulfadiazine
35%
Randomized Controlled Trial
23%
Wound Infection
23%
Helix Aspersa
11%
Antimicrobial Agent
11%
Clinical Trial
5%
Endocrine Therapy
5%
Gentamicin
5%
Topical Agent
5%
Growth Hormone
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Procedural Pain
5%
Mafenide Acetate
5%
Bacitracin
5%
Diseases
5%